This analysis also showed expected agreements across all comparisons including LME-IN and LE4 (κ = 0.47), both characterized by immune cell infiltration and inflammation, TME26 negative and LME-DE (κ = 0.43), both lacking immune cells, MCD with MYD88 (κ = 0.3), both of which harbor MYD88 mutations, and EZB with BCL2 (κ = 0.27), both classified by mutations in BCL2 and EZH2. Together, these data suggests that our new risk signature is unique and identifies high risk cases across existing DLBCL classifiers. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.